Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin Monotherapy in RRMM With Normal and Impaired Renal Function
NCT04398745Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2020
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of belantamab mafodotin in multiple myeloma (MM) (4 arms), sponsored by GSK. Primary endpoints: Area Under the Concentration-time Curve to Last Quantifiable Timepoint, Area Under the Concentration-time Curve During the Dosing Interval and 6 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04398745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398745.